Oncimmune Holdings plc
Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse ev… Read more
Market Cap & Net Worth: Oncimmune Holdings plc (ONC)
Oncimmune Holdings plc (LSE:ONC) has a market capitalization of $15.50K (GBX127.42 Million) as of March 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #49854 globally and #1424 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Oncimmune Holdings plc's stock price GBX1.14 by its total outstanding shares 111773000 (111.77 Million).
Oncimmune Holdings plc Market Cap History: 2016 to 2025
Oncimmune Holdings plc's market capitalization history from 2016 to 2025. Data shows change from $1.79 Million to $15.50K (-41.62% CAGR).
Index Memberships
Oncimmune Holdings plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$41.09 Million | 0.00% | #375 of 722 |
Weight: Oncimmune Holdings plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Oncimmune Holdings plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Oncimmune Holdings plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.07x
Oncimmune Holdings plc's market cap is 0.07 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.79 Million | $430.00K | -$8.44 Million | 4.16x | N/A |
| 2017 | $1.43 Million | $215.00K | -$5.02 Million | 6.64x | N/A |
| 2018 | $1.56 Million | $240.00K | -$6.31 Million | 6.52x | N/A |
| 2019 | $523.58K | $171.00K | -$8.01 Million | 3.06x | N/A |
| 2020 | $2.24 Million | $509.00K | -$8.46 Million | 4.40x | N/A |
| 2021 | $2.38 Million | $3.72 Million | -$4.63 Million | 0.64x | N/A |
| 2022 | $788.77K | $3.86 Million | -$9.51 Million | 0.20x | N/A |
| 2023 | $342.71K | $1.15 Million | $4.10 Million | 0.30x | 0.08x |
| 2024 | $195.15K | $2.74 Million | -$3.63 Million | 0.07x | N/A |
Competitor Companies of ONC by Market Capitalization
Companies near Oncimmune Holdings plc in the global market cap rankings as of March 19, 2026.
Key companies related to Oncimmune Holdings plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Oncimmune Holdings plc Historical Marketcap From 2016 to 2025
Between 2016 and today, Oncimmune Holdings plc's market cap moved from $1.79 Million to $ 15.50K, with a yearly change of -41.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX15.50K | -92.06% |
| 2024 | GBX195.15K | -43.06% |
| 2023 | GBX342.71K | -56.55% |
| 2022 | GBX788.77K | -66.86% |
| 2021 | GBX2.38 Million | +6.38% |
| 2020 | GBX2.24 Million | +327.27% |
| 2019 | GBX523.58K | -66.52% |
| 2018 | GBX1.56 Million | +9.52% |
| 2017 | GBX1.43 Million | -20.15% |
| 2016 | GBX1.79 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 16th, 2026 the market cap of Oncimmune Holdings plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.50K USD |
| MoneyControl | $15.50K USD |
| MarketWatch | $15.50K USD |
| marketcap.company | $15.50K USD |
| Reuters | $15.50K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.